These data suggest that the high cell cycle activity of cancer cells predicts a poor response to T-DM1 and that CDK4/6 inhibitors may reverse resistance,26 providing a new strategy for treating HER2-positive breast cancer. Here, ERBB2 is linked to breast carcinoma.